IS8008A - Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu - Google Patents

Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu

Info

Publication number
IS8008A
IS8008A IS8008A IS8008A IS8008A IS 8008 A IS8008 A IS 8008A IS 8008 A IS8008 A IS 8008A IS 8008 A IS8008 A IS 8008A IS 8008 A IS8008 A IS 8008A
Authority
IS
Iceland
Prior art keywords
composition
progestin
endometriosis
estrogen
treatment
Prior art date
Application number
IS8008A
Other languages
English (en)
Other versions
IS2547B (is
Inventor
Rubin Stephen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8008A publication Critical patent/IS8008A/is
Publication of IS2547B publication Critical patent/IS2547B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8008A 2003-02-05 2005-08-30 Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu IS2547B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (2)

Publication Number Publication Date
IS8008A true IS8008A (is) 2005-08-30
IS2547B IS2547B (is) 2009-10-15

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8008A IS2547B (is) 2003-02-05 2005-08-30 Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu

Country Status (30)

Country Link
US (2) US7910570B2 (is)
EP (2) EP1589976B1 (is)
JP (2) JP4658918B2 (is)
KR (1) KR101075929B1 (is)
CN (1) CN100393360C (is)
AR (1) AR043013A1 (is)
AT (1) ATE374612T1 (is)
AU (1) AU2004210184B2 (is)
BR (1) BRPI0407039A (is)
CA (1) CA2513910C (is)
CO (1) CO5580789A2 (is)
CY (1) CY1107816T1 (is)
DE (1) DE602004009288T2 (is)
DK (1) DK1589976T3 (is)
ES (1) ES2293215T3 (is)
GB (1) GB0302572D0 (is)
HK (1) HK1082918A1 (is)
IL (1) IL169583A0 (is)
IS (1) IS2547B (is)
MX (1) MXPA05008347A (is)
MY (1) MY140723A (is)
NO (1) NO20053626L (is)
NZ (1) NZ541222A (is)
PL (1) PL214680B1 (is)
PT (1) PT1589976E (is)
RU (2) RU2360681C2 (is)
TW (1) TWI354556B (is)
UA (1) UA80741C2 (is)
WO (1) WO2004069260A1 (is)
ZA (1) ZA200506221B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CA2585832A1 (en) * 2004-10-04 2006-04-20 Wayne State University Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
EP0462189B1 (en) * 1989-03-10 1995-09-27 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
WO1999063973A2 (en) 1998-06-11 1999-12-16 Endorecherche, Inc. PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
WO2002030355A2 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
DK1377298T3 (da) 2001-01-26 2007-01-02 Pfizer Italia Srl Exemestan til behandling af hormon-afhængige lidelser
AU2002240949A1 (en) 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
AU2002342163B2 (en) 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
EP1469861A1 (en) 2002-01-22 2004-10-27 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
AU2003213956A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
WO2003082336A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Female birth control method
AU2003213957A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
US20040120956A1 (en) * 2002-06-27 2004-06-24 Song Xiao-Yu R. CNGH0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
IL169583A0 (en) 2007-07-04
BRPI0407039A (pt) 2006-01-17
CN100393360C (zh) 2008-06-11
ATE374612T1 (de) 2007-10-15
CA2513910A1 (en) 2004-08-19
EP1589976B1 (en) 2007-10-03
MXPA05008347A (es) 2005-11-04
US7910570B2 (en) 2011-03-22
CA2513910C (en) 2012-04-03
DE602004009288D1 (de) 2007-11-15
RU2008138166A (ru) 2010-03-27
KR20050098296A (ko) 2005-10-11
TW200503731A (en) 2005-02-01
PT1589976E (pt) 2007-11-22
US20110009373A1 (en) 2011-01-13
CY1107816T1 (el) 2013-06-19
RU2005127667A (ru) 2006-03-27
WO2004069260A1 (en) 2004-08-19
ES2293215T3 (es) 2008-03-16
TWI354556B (en) 2011-12-21
IS2547B (is) 2009-10-15
PL214680B1 (pl) 2013-09-30
MY140723A (en) 2010-01-15
NZ541222A (en) 2008-12-24
JP2011001388A (ja) 2011-01-06
NO20053626L (no) 2005-08-26
AU2004210184B2 (en) 2007-01-04
PL377939A1 (pl) 2006-02-20
AR043013A1 (es) 2005-07-13
CO5580789A2 (es) 2005-11-30
CN1747736A (zh) 2006-03-15
DK1589976T3 (da) 2007-12-27
EP1857111A3 (en) 2009-03-04
DE602004009288T2 (de) 2008-07-10
JP2006516602A (ja) 2006-07-06
ZA200506221B (en) 2006-05-31
GB0302572D0 (en) 2003-03-12
EP1857111A2 (en) 2007-11-21
US20060142256A1 (en) 2006-06-29
RU2360681C2 (ru) 2009-07-10
UA80741C2 (en) 2007-10-25
EP1589976A1 (en) 2005-11-02
JP4658918B2 (ja) 2011-03-23
KR101075929B1 (ko) 2011-10-26
HK1082918A1 (en) 2006-06-23
AU2004210184A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
IS2547B (is) Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
EP1812049A4 (en) KALLIKREIN INHIBITORS AND USES THEREOF
EP1824842A4 (en) INHIBITORS OF 11-HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHOD OF USE
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
IS2565B (is) Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk í sermi
GB2434983B (en) Methods and compositions for wound healing
IL175858A0 (en) Extended use combination comprising estrogens and progestins
DK1623711T3 (da) Eksternt plaster indeholdende östrogen og/eller progestogen
IL173188A0 (en) Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
EP1534278A4 (en) NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
NO20071297L (no) Farmasøytisk sammenseting omfattende drospirenon og etynylestradiol
AU2003275268A8 (en) Hemostatic compositions and methods
EP1668068A4 (en) TEXTURED JOINT MASS, DISTRIBUTION DEVICE AND METHOD OF USE
EP1688126A4 (en) PARAKERATOSE INHIBITORS AND SKIN EXTERNAL COMPOSITION
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
IL182844A0 (en) Topical compositions containing androgens for preventing skin aging and methods utilyzing the same
EP1679348A4 (en) PULP COMPOSITION AND USE THEREOF
EP1583528A4 (en) NF-KB INHIBITORS AND ITS USES
EP1782838A4 (en) INHIBITION OF INFILTRATION AND AGENT TAKING CELLS
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze
GB0323240D0 (en) Creatine composition and use
NO20041010L (no) 17-alfa-hydroksy-14-beta-steroider med hormonal effekt